Biosimilar Fact Sheet

Further information on Abzena’s CHO, NS0 and Sp2/0 biosimilar cell line development programmes with bespoke quality[...]





Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development

Cambridge, UK 21 March 2019 – Abzena, the leading biologics target to GMP partner research organisation (PRO),[...] Read more

Abzena and Lipum AB sign integrated CMC agreement to produce a novel biologic for autoimmune inflammatory diseases

  San Diego, USA, 19 March 2019 – Abzena, the global biologics gene to GMP partner research organization, announced[...] Read more

Abzena and Telix sign strategic manufacturing and bioconjugation agreement

Cambridge, UK and Melbourne, Australia, 2 July 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group[...] Read more

Interested in our services? Get In Touch